Zobrazeno 1 - 10
of 204
pro vyhledávání: '"J, Maurath"'
Autor:
Jay L. Goldstein, Nikos Maniadakis, Thomas A. Burke, Clement J. Maurath, Richard A. Zabinski, D. Pettitt
Publikováno v:
PharmacoEconomics. 19:33-47
Objective: The purpose of this study is to provide a framework for estimating the economic efficiency of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), concomitant gastroprotective agents (GPAs) to reduce the risk of NSAID toxicity, and
Autor:
Jay L. Goldstein, J Kaiser, C J Maurath, Naurang M. Agrawal, Kenneth M. Verburg, Richard C. Hubbard, G S Geis, Fred E. Silverstein
Publikováno v:
American Journal of Gastroenterology. 95:1681-1690
The aim of this study was to assess the rate of upper gastrointestinal (UGI) ulcer complications (bleeding, perforation, or gastric outlet obstruction) associated with celecoxib, a specific COX-2 inhibitor, compared with the rate associated with nons
Publikováno v:
American Journal of Therapeutics. 7:159-174
The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Conventional treatment for these debilitating conditions routinely involves the use of conventional
Clinical system for simultaneous external superficial microwave hyperthermia and cobalt-60 radiation
Publikováno v:
International Journal of Hyperthermia. 11:11-26
A system for simultaneous thermoradiotherapy was devised to investigate the possible benefits and/or complications of thermal radiosensitization in human superficial tumours. The system combines the well-known treatment modalities of external 915 MHz
Autor:
Luis M. Ruilope-Urioste, Scott Krause, Jay H. Kleiman, Yves Lacourcière, Barbara Roniker, Ellen Burgess, Clement J. Maurath, Suzanne Oparil
Publikováno v:
Clinical therapeutics. 25(9)
Even within the normal range, aldosterone levels are linked to end-organ toxicity and mortality in patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers does not sufficiently reduce plasm
Publikováno v:
American journal of therapeutics. 7(3)
Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associat
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
W G, Bensen, S Z, Zhao, T A, Burke, R A, Zabinski, R W, Makuch, C J, Maurath, N M, Agrawal, G S, Geis
Publikováno v:
The Journal of rheumatology. 27(8)
To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA).An analysis of 5, 12-week, randomized, double blind, parallel group, placebo controlled c
Autor:
Alan L. Hillman, Clem J. Maurath, Michael E. Mason, Patricia A. Deverka, Joseph E. Oesterling, J. Sanford Schwartz, Claus G. Roehrborn, Robert J. Padley, Ellen Peskin, Mary Kaye Willian
Publikováno v:
Urology. 47(2)
Objectives To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha,-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Metho
Autor:
J R, Simpson, K M, Rich, R E, Drzymala, T H, Wasserman, E E, Klein, M, Michaletz-Lorenz, J, Maurath, E, Filiput
Publikováno v:
Missouri medicine. 92(4)
From February 1989 to December 1993, 139 patients with a variety of brain lesions were treated with stereotactic external beam irradiation using a 6MV linear accelerator. The largest group consisted of patients with recurrent brain metastases (n = 46